Payden & Rygel Sells 3,500 Shares of Johnson & Johnson $JNJ

Payden & Rygel reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 61,400 shares of the company’s stock after selling 3,500 shares during the period. Payden & Rygel’s holdings in Johnson & Johnson were worth $12,707,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Brighton Jones LLC boosted its holdings in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. United Bank increased its stake in Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock valued at $1,539,000 after buying an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC increased its stake in Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after buying an additional 692 shares during the last quarter. Wealth Group Ltd. boosted its stake in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after buying an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. grew its holdings in shares of Johnson & Johnson by 9.8% in the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after acquiring an additional 6,584 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Timothy Schmid sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Leerink Partners upgraded Johnson & Johnson to Outperform from Market Perform and raised its price target to $265, citing strong new-drug momentum and improved growth prospects. Article: Is Johnson & Johnson (JNJ) One of the Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026?
• Positive Sentiment: J&J’s oncology pipeline received attention after the company presented encouraging early/Phase 2 data for JNJ-1900 (NBTXR3) in inoperable lung cancer, reinforcing the company’s cancer-treatment growth story. Article: Johnson & Johnson Lung Cancer Data Adds Dimension To Oncology Valuation Story
• Positive Sentiment: Multiple articles highlighted Johnson & Johnson as a strong dividend and “Dogs of the Dow” name, which supports the stock’s defensive appeal for income-focused investors. Article: Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
• Neutral Sentiment: Nanobiotix also said J&J presented Part 1 data from the CONVERGE study, adding more visibility to the company’s oncology collaboration, though the market impact appears limited so far. Article: Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer
• Negative Sentiment: The U.S. Supreme Court declined to hear a challenge to the Medicare drug-price negotiation program, leaving intact a policy that could continue to pressure pricing for Johnson & Johnson’s pharmaceutical business. Article: Supreme Court Rejects Drugmakers’ Challenge to Medicare Price Negotiation Program

Johnson & Johnson Stock Performance

Shares of JNJ opened at $228.80 on Tuesday. Johnson & Johnson has a 1 year low of $149.04 and a 1 year high of $251.71. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The stock’s fifty day moving average price is $234.91 and its two-hundred day moving average price is $222.31. The firm has a market cap of $550.76 billion, a PE ratio of 26.45, a PEG ratio of 2.22 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter in the prior year, the company earned $2.77 EPS. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. Johnson & Johnson’s dividend payout ratio is 60.12%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. TD Cowen began coverage on Johnson & Johnson in a research report on Wednesday, April 8th. They issued a “buy” rating and a $250.00 price objective on the stock. Stifel Nicolaus lifted their target price on Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, April 15th. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a report on Wednesday, April 15th. Guggenheim increased their price target on shares of Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Finally, Johnson Rice raised shares of Johnson & Johnson from a “hold” rating to an “outperform” rating in a research report on Wednesday, May 13th. Twenty research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $253.04.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.